Smith, D C <br/><br/>
Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Jun 1999 
 - 1664-71 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.1999.17.6.1664  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bone Neoplasms--drug therapy<br/>Drug Resistance, Neoplasm<br/>Estramustine--administration & dosage<br/>Etoposide--administration & dosage<br/>Humans<br/>Male<br/>Middle Aged<br/>Paclitaxel--administration & dosage<br/>Prostatic Neoplasms--drug therapy<br/>Quality of Life<br/>Soft Tissue Neoplasms--drug therapy<br/>Survival Rate<br/>Treatment Outcome